Vasavan N.P. Nair, McGill University
Professor
Psychiatry
Montreal, Quebec
vasavan.nair@douglas.mcgill.ca
Office:
(514) 762-3035
Expert In
Bio/Research
Dr. Nair is currently Director of Human Psychopharmacology Trials at the Douglas Mental Health University Institute. He is also the Medical Chief of the Program of Dementia with Psychiatric Comorbidity in the same institution. Dr. Nair joined the Douglas Hospital in 1972. He was responsible for e...
Click to Expand >>
Click to Expand >>
Bio/Research
Dr. Nair is currently Director of Human Psychopharmacology Trials at the Douglas Mental Health University Institute. He is also the Medical Chief of the Program of Dementia with Psychiatric Comorbidity in the same institution. Dr. Nair joined the Douglas Hospital in 1972. He was responsible for establishing the Douglas Hospital Research Centre and was its scientific director from its inception in 1980 to 1995. During his directorship, he set up the technological infrastructure and team oriented interdisciplinary research teams. This model has sustained the growth of the Research Centre and continues to do so today.
His major research interest has been in psychopharmacology and in biomarkers of brain aging, with a view to the prevention of Alzheimer’s disease. He set up a longitudinal study of brain aging that started as a WHO-sponsored multinational study in 1982 and continues now as a Douglas Institute program. Currently, he is engaged in the clinical trial of a ß-Amyloid antibody (passive vaccine) in Alzheimer’s disease.
At McGill, he is a full Professor in the Department of Psychiatry and at the McGill Centre for Studies in Aging. He has been a scientific reviewer for the National Institute of Health in the USA from 1991-1995. He has published over 225 articles in peer-reviewed journals and made over 190 presentations. He has received a number of honours, one being the medal of honour of the Canadian College of Neuropsychopharmacology. Recently, he has been nominated for the fellowship of the American Psychiatric Association.
Click to Shrink <<
His major research interest has been in psychopharmacology and in biomarkers of brain aging, with a view to the prevention of Alzheimer’s disease. He set up a longitudinal study of brain aging that started as a WHO-sponsored multinational study in 1982 and continues now as a Douglas Institute program. Currently, he is engaged in the clinical trial of a ß-Amyloid antibody (passive vaccine) in Alzheimer’s disease.
At McGill, he is a full Professor in the Department of Psychiatry and at the McGill Centre for Studies in Aging. He has been a scientific reviewer for the National Institute of Health in the USA from 1991-1995. He has published over 225 articles in peer-reviewed journals and made over 190 presentations. He has received a number of honours, one being the medal of honour of the Canadian College of Neuropsychopharmacology. Recently, he has been nominated for the fellowship of the American Psychiatric Association.
Click to Shrink <<